Non-inferiority of Belotero® Basic Versus Juvéderm® Ultra 3

This study has been completed.
Sponsor:
Information provided by:
Merz Pharmaceuticals GmbH
ClinicalTrials.gov Identifier:
NCT01305187
First received: February 25, 2011
Last updated: June 17, 2011
Last verified: June 2011

February 25, 2011
June 17, 2011
February 2011
May 2011   (final data collection date for primary outcome measure)
The proportion of subjects reporting an equal or better outcome for the side of face treated with Belotero® Basic compared to the side of face treated with Juvéderm® Ultra 3 at V4 on the validated Wrinkle Severity Rating Scale II [ Time Frame: Week 4 ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01305187 on ClinicalTrials.gov Archive Site
  • Overall intra-individual change at V2 post implantation in the validated Wrinkle Severity Rating Scale II compared to V2 pre implantation [ Time Frame: Week 0 ] [ Designated as safety issue: No ]
  • Overall intra-individual change at V3 post implantation in the validated Wrinkle Severity Rating Scale II compared to V2 pre implantation [ Time Frame: 2 Weeks ] [ Designated as safety issue: No ]
  • Overall intra-individual change at V4 post implantation in the validated Wrinkle Severity Rating Scale II compared to V2 pre implantation [ Time Frame: 4 Weeks ] [ Designated as safety issue: No ]
  • Overall absolute score change at V2 post implantation in the validated Wrinkle Severity Rating Scale II compared to V2 pre implantation assessed by photo rating of one independent rater [ Time Frame: Week 0 ] [ Designated as safety issue: No ]
  • Overall absolute score change at V3 post implantation in the validated Wrinkle Severity Rating Scale II compared to V2 pre implantation assessed by photo rating of one independent rater [ Time Frame: 2 Weeks ] [ Designated as safety issue: No ]
  • Overall absolute score change at V4 post implantation in the validated Wrinkle Severity Rating Scale II compared to V2 pre implantation assessed by photo rating of one independent rater [ Time Frame: 4 Weeks ] [ Designated as safety issue: No ]
  • Proportion of overall responders i.e. at least 1 point improvement in the validated Wrinkle Severity Rating Scale II(WSRS II) at V4, based on the intra-individual change in WSRS II compared to baseline before implantation, V2 pre implantation [ Time Frame: 4 Weeks ] [ Designated as safety issue: No ]
  • Assessment of Global aesthetic improvement [GAIS] by the investigator and subject V2 post implantation and V4 [ Time Frame: 4 Weeks ] [ Designated as safety issue: No ]
  • Overall GAIS by photo rating of an individual rater V2 post implantation and V4 [ Time Frame: 4 Weeks ] [ Designated as safety issue: No ]
  • Subject Satisfaction Questionnaire results at V2 pre and post implantation [ Time Frame: Week 0 ] [ Designated as safety issue: No ]
  • Subject Satisfaction Questionnaire results at V3 [ Time Frame: 2 Weeks ] [ Designated as safety issue: No ]
  • Subject Satisfaction Questionnaire results at V4 [ Time Frame: 4 Weeks ] [ Designated as safety issue: No ]
  • Global assessment of subject comfort at V2 post implantation by the investigator and the subject. [ Time Frame: Week 0 ] [ Designated as safety issue: No ]
  • Global assessment of subject comfort at V3 by the investigator and the subject [ Time Frame: 2 Weeks ] [ Designated as safety issue: No ]
  • Global assessment of subject comfort at V4 by the investigator and the subject [ Time Frame: 4 Weeks ] [ Designated as safety issue: No ]
  • Proportion of subjects feeling the implant at V2 post implantation [ Time Frame: Week 0 ] [ Designated as safety issue: No ]
  • Proportion of subjects feeling the implant at V3. [ Time Frame: 2 Weeks ] [ Designated as safety issue: No ]
  • Proportion of subjects feeling the implant at V4 [ Time Frame: 4 Weeks ] [ Designated as safety issue: No ]
  • Proportion of subjects recommending Belotero® Basic only or Juvéderm® Ultra 3 only or both at V4 [ Time Frame: 4 Weeks ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Non-inferiority of Belotero® Basic Versus Juvéderm® Ultra 3
Monocentric, Randomized, Subject and Rater Blinded Clinical Investigation to Prove the Non-inferiority of Belotero® Basic Versus Juvéderm® Ultra 3 Containing Lidocaine - After Single Injection for Correction of Nasolabial Folds (NLF)

This study will investigate the non-inferiority of Belotero® Basic versus Juvéderm® Ultra 3 in the treatment of nasolabial folds

Not Provided
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Outcomes Assessor)
Primary Purpose: Treatment
  • Physiological Stress
  • Disorder of Aging
  • Skin Diseases
  • Wrinkles
  • Nasolabial Folds
Device: Hyaluronic Acid Filler
The dosage is individualized depending on the depth of the NLF. The goal is to achieve optimal correction of both NLF with single implantations of Belotero® Basic and Juvéderm® Ultra 3 respectively. Each subject will be injected with Belotero® Basic and Lidocaine containing Juvéderm® Ultra 3 according to a split-face design. The allocation of fillers to the side of the face will be randomized. The randomization method is block-wise with a ratio 1:1 to the groups Belotero® Basic left and Juvéderm® Ultra 3 right, Belotero® Basic right and Juvéderm® Ultra 3 left.
Experimental: Hyaluronic Acid Filler - Medical Device
Intervention: Device: Hyaluronic Acid Filler
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
40
May 2011
May 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subject with bilateral, symmetrical NLF and wish for correction. Documented severity of NLF score 2 or 3 at screening on the Merz Wrinkle Severity Rating Scale II

Exclusion Criteria:

  • Any severe or uncontrolled systemic disease (e.g. cardiac, renal, pulmonary, hepatic, or gastrointestinal). Subject suffering from diabetes mellitus, autoimmune and rheumatic diseases, clinically relevant coagulation disorders, recurrent angina, or severe psychic, neurological or mental disease
  • History of malignancy within the last 5 years before the study
  • Infection, inflammations or active dermatological disease in the face
Both
18 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
Germany
 
NCT01305187
MRZ 90028_4007_0
No
Dr. Matthias Zerm, Manager Public Disclosure, Merz Pharmaceuticals GmbH
Merz Pharmaceuticals GmbH
Not Provided
Study Director: Clemens Acker, Dr. Merz Pharmaceuticals GmbH
Merz Pharmaceuticals GmbH
June 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP